Company / Gross Margin
ADMA Biologics, Inc. Gross Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
57.4%
FY2025
5-year range
1.5% / 57.4%
FY2021-FY2025
Trend
+11.5%
vs FY2024
Sector context
#15 of 28
Health Care
What the data says
At 57.4%, ADMA Biologics, Inc.'s gross margin ranks #15 of 28 in the Health Care sector. Gross Margin has increased for 3 consecutive years, from 1.5% in FY2022 to 57.4% in FY2025.
Based on SEC 10-K filings.
57.4% in FY2025 with a 5-year CAGR of +102.6%.
Improved from 34.4% to 57.4% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- +55.9pp
- 5-Year Change
- +102.6pp
- 10-Year Change
- -
Sector benchmark
#15 of 28 in Health CareTop 54% of 28This company 57.4% Sector average 60.3%
▼
-4.8% below sector average
Key checks
Key Insights
- ADMA Biologics, Inc.'s gross margin has grown for 3 consecutive years.
- In FY2025, gross margin increased 11.5% year-over-year.
- Currently 2.9pp below the Health Care sector average.
- Lowest gross margin in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 57.4% | +11.5% |
| FY2024 | 51.5% | +49.5% |
| FY2023 | 34.4% | +2275.2% |
| FY2022 | 1.5% | +0.0% |
| FY2021 | 1.5% | +103.2% |
| FY2020 | -45.2% | - |
| FY2019 | - | - |
| FY2018 | -148.4% | -467.9% |
| FY2017 | 40.3% | +0.0% |
| FY2016 | 40.3% | +9.8% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026